Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors

Research output: Contribution to journalArticle

Abstract

Imatinib mesylate is a molecular-targeted agent, shown to be effective in chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The latter may currently serve as a model on which speculating how the future of molecular-targeted therapy in solid tumors will be. So far, some lessons have been learnt. 1) Molecular-targeted therapy can be effective in the advanced disease setting, resulting in major tumor responses. 2) Patterns of tumor responses may be peculiar, radiologically and pathologically. 3) Anti-tumor activity may be highly predictable by assessing tumor molecular biology. 4) The methodology of clinical development of molecular-targeted agents may differ from standard chemotherapy in some respects, because, say, the preclinical rationale may be stronger, thus increasing the Bayesian prior probability of efficacy, or the optimal dose cannot be determined separately from the assessment of activity and efficacy. 5) Molecular-targeted agents will hardly remain "orphan drugs", if effective. 6) While an obvious impact on survival in the advanced disease setting has been clearly demonstrated, the biologic and clinical impact of molecular-targeted therapy still needs to be elucidated. Its eradicating capabilities, as well as the implications of secondary resistance, are to be understood. 7) Integrated, multimodality approaches, including surgery, may still be of value in the molecular-targeted therapy era.

Original languageEnglish
Pages (from-to)55-58
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 4
Publication statusPublished - Nov 2004

Fingerprint

Gastrointestinal Stromal Tumors
Molecular Targeted Therapy
Neoplasms
Orphan Drug Production
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Biology
Imatinib Mesylate
Drug Therapy

Keywords

  • GIST
  • Imatinib
  • Molecular-targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. / Casali, Paolo G.; Bertulli, R.; Fumagalli, E.; Coco, P.; Grosso, F.; Stacchiotti, S.

In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 4, 11.2004, p. 55-58.

Research output: Contribution to journalArticle

@article{8134ab332bf541d7bd5d49259272688a,
title = "Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors",
abstract = "Imatinib mesylate is a molecular-targeted agent, shown to be effective in chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The latter may currently serve as a model on which speculating how the future of molecular-targeted therapy in solid tumors will be. So far, some lessons have been learnt. 1) Molecular-targeted therapy can be effective in the advanced disease setting, resulting in major tumor responses. 2) Patterns of tumor responses may be peculiar, radiologically and pathologically. 3) Anti-tumor activity may be highly predictable by assessing tumor molecular biology. 4) The methodology of clinical development of molecular-targeted agents may differ from standard chemotherapy in some respects, because, say, the preclinical rationale may be stronger, thus increasing the Bayesian prior probability of efficacy, or the optimal dose cannot be determined separately from the assessment of activity and efficacy. 5) Molecular-targeted agents will hardly remain {"}orphan drugs{"}, if effective. 6) While an obvious impact on survival in the advanced disease setting has been clearly demonstrated, the biologic and clinical impact of molecular-targeted therapy still needs to be elucidated. Its eradicating capabilities, as well as the implications of secondary resistance, are to be understood. 7) Integrated, multimodality approaches, including surgery, may still be of value in the molecular-targeted therapy era.",
keywords = "GIST, Imatinib, Molecular-targeted therapy",
author = "Casali, {Paolo G.} and R. Bertulli and E. Fumagalli and P. Coco and F. Grosso and S. Stacchiotti",
year = "2004",
month = "11",
language = "English",
volume = "16",
pages = "55--58",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors

AU - Casali, Paolo G.

AU - Bertulli, R.

AU - Fumagalli, E.

AU - Coco, P.

AU - Grosso, F.

AU - Stacchiotti, S.

PY - 2004/11

Y1 - 2004/11

N2 - Imatinib mesylate is a molecular-targeted agent, shown to be effective in chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The latter may currently serve as a model on which speculating how the future of molecular-targeted therapy in solid tumors will be. So far, some lessons have been learnt. 1) Molecular-targeted therapy can be effective in the advanced disease setting, resulting in major tumor responses. 2) Patterns of tumor responses may be peculiar, radiologically and pathologically. 3) Anti-tumor activity may be highly predictable by assessing tumor molecular biology. 4) The methodology of clinical development of molecular-targeted agents may differ from standard chemotherapy in some respects, because, say, the preclinical rationale may be stronger, thus increasing the Bayesian prior probability of efficacy, or the optimal dose cannot be determined separately from the assessment of activity and efficacy. 5) Molecular-targeted agents will hardly remain "orphan drugs", if effective. 6) While an obvious impact on survival in the advanced disease setting has been clearly demonstrated, the biologic and clinical impact of molecular-targeted therapy still needs to be elucidated. Its eradicating capabilities, as well as the implications of secondary resistance, are to be understood. 7) Integrated, multimodality approaches, including surgery, may still be of value in the molecular-targeted therapy era.

AB - Imatinib mesylate is a molecular-targeted agent, shown to be effective in chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The latter may currently serve as a model on which speculating how the future of molecular-targeted therapy in solid tumors will be. So far, some lessons have been learnt. 1) Molecular-targeted therapy can be effective in the advanced disease setting, resulting in major tumor responses. 2) Patterns of tumor responses may be peculiar, radiologically and pathologically. 3) Anti-tumor activity may be highly predictable by assessing tumor molecular biology. 4) The methodology of clinical development of molecular-targeted agents may differ from standard chemotherapy in some respects, because, say, the preclinical rationale may be stronger, thus increasing the Bayesian prior probability of efficacy, or the optimal dose cannot be determined separately from the assessment of activity and efficacy. 5) Molecular-targeted agents will hardly remain "orphan drugs", if effective. 6) While an obvious impact on survival in the advanced disease setting has been clearly demonstrated, the biologic and clinical impact of molecular-targeted therapy still needs to be elucidated. Its eradicating capabilities, as well as the implications of secondary resistance, are to be understood. 7) Integrated, multimodality approaches, including surgery, may still be of value in the molecular-targeted therapy era.

KW - GIST

KW - Imatinib

KW - Molecular-targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=11244273975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244273975&partnerID=8YFLogxK

M3 - Article

C2 - 15688611

AN - SCOPUS:11244273975

VL - 16

SP - 55

EP - 58

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 4

ER -